UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000026069
Receipt number R000029951
Scientific Title Determination of glycemic index (GI) of bread
Date of disclosure of the study information 2017/02/10
Last modified on 2017/08/14 13:57:37

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Determination of glycemic index (GI) of bread

Acronym

Determination of glycemic index (GI) of bread.

Scientific Title

Determination of glycemic index (GI) of bread

Scientific Title:Acronym

Determination of glycemic index (GI) of bread.

Region

Japan


Condition

Condition

Healthy subjects

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Determination of glycemic index (GI) of bread.

Basic objectives2

Bio-availability

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Glycemic index(GI)

Key secondary outcomes

Postprandial blood glucose level,
Postprandial maximum blood glucose level,
Incremental blood glucose area under the curve
GI; Subjects with fasting plasma glucose <100 mg/dL, and =>100 mg/dL, respectively.


Base

Study type

Interventional


Study design

Basic design

Cross-over

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Glucose solution as reference (50g/150ml)
wash out period (at least 5 days)
bread A
wash out period (at least 5 days)
bread B

Interventions/Control_2

Glucose solution as reference (50g/150ml)
wash out period (at least 5 days)
bread B
wash out period (at least 5 days)
bread A

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

51 years-old >

Gender

Male and Female

Key inclusion criteria

(1) Aged between 20 and 50 years old at consent.
(2) Fasting plasma glucose 70-126mg/dl
(3) Subjects whose body mass index (BMI) is under 30kg/m2
(4) Subjects who understand the study procedures and agree to participate in the study by giving informed consent prior to the study.

Key exclusion criteria

1) Subjects who have history of malignant diseases.
2) Subjects who have previous and/or current medical history of serious disease (e.g., heart, liver, kidney, organ).
3) Subjects who have previous medical history of drug and/or food allergy.
4) Subjects who have infectious diseases.
5) Subjects who have continuous intake of medicine and/or health food for carbohydrate metabolism
6) Subjects who donated over 200 mL blood within the last one month, and/or over 400 mL blood within the last three month.
7) Subjects with impaired glucose tolerance.
8) Subjects who is menstruating in this clinical test.
9) Females who are pregnant or lactating, and who could become pregnant or lactating during test period.
10) Subjects who plan to participate in other clinical tests.
11) Subjects who are not eligible for this study for some medical reasons.

Target sample size

26


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Katsuhisa Sakano

Organization

CPCC Company Limited

Division name

Clinical Research Planning Department

Zip code


Address

4F Chushin Build. 3-3-5 Uchikanda Chiyoda-ku, Tokyo 101-0047 Japan

TEL

03-5297-3112

Email

k.s@cpcc.co.jp


Public contact

Name of contact person

1st name
Middle name
Last name Makoto Ichinohe

Organization

CPCC Company Limited

Division name

Plan Sales Department

Zip code


Address

4F Chushin Build. 3-3-5 Uchikanda Chiyoda-ku, Tokyo 101-0047 Japan

TEL

03-5297-3112

Homepage URL


Email

m.i@cpcc.co.jp


Sponsor or person

Institute

CPCC Company Limited

Institute

Department

Personal name



Funding Source

Organization

Nisshin Seifun Group Inc.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2017 Year 02 Month 10 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2017 Year 01 Month 19 Day

Date of IRB


Anticipated trial start date

2017 Year 02 Month 11 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded

2017 Year 03 Month 30 Day


Other

Other related information



Management information

Registered date

2017 Year 02 Month 09 Day

Last modified on

2017 Year 08 Month 14 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000029951


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name